0002001011-24-000078.txt : 20240826 0002001011-24-000078.hdr.sgml : 20240826 20240826201537 ACCESSION NUMBER: 0002001011-24-000078 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240822 FILED AS OF DATE: 20240826 DATE AS OF CHANGE: 20240826 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Korenberg Matthew E CENTRAL INDEX KEY: 0001649903 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 241242936 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-08-22 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001649903 Korenberg Matthew E 555 HERITAGE DRIVE SUITE 200 JUPITER FL 33458 0 1 0 0 President & COO 0 Common Stock 2024-08-22 4 S 0 1157 105.54 D 67211 D Common Stock 2024-08-23 4 S 0 2037 104.0945 D 65174 D Common Stock 2024-08-23 4 S 0 4275 105.1319 D 60899 D Common Stock 2024-08-26 4 S 0 6177 105.016 D 54722 D Common Stock 2024-08-26 4 S 0 5212 106.3214 D 49510 D The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.2500 to $105.6500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.0000 to $105.4450. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.7200 to $105.6700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.8100 to $106.6900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. By: /s/ Andrew Reardon, Attorney-in-Fact For: Matthew E. Korenberg 2024-08-26